# US 12,006,322 B2 · Substituted pyridines as PARP1 inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,006,322 B2
- Document ID: US12006322B2
- Status: Granted
- Kind: B2
- Application number: 18/471,250
- Filed: 2023-09-20
- Published: 2024-04-04
- Granted: 2024-06-11
- Earliest claimed: 2022-04-28
- Assignees: Xin Thera, Inc.
- Applicants: Xinthera, Inc.
- Inventors: Robert L. Hoffman; Porino Jinjo Va; Joseph Robert Pinchman; Qing Dong; Stephen W. Kaldor
- Web page: https://patentgrep.com/patent/US12006322B2

## CPC

- A61P 35/00: Antineoplastic agents
- C07D 487/04: Ortho-condensed systems
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- C07D 471/04: Ortho-condensed systems
- C07D 491/04: Ortho-condensed systems
- C07D 491/048: the oxygen-containing ring being five-membered
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Described herein are tricyclic PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer and are of Formula (Ip):

## Claims

### Claim 1

A compound:
or a pharmaceutically acceptable salt or tautomer thereof.

### Claim 2 (depends on 1)

A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the compound of claim 1, or a pharmaceutically acceptable salt or tautomer thereof.

### Claim 3

A compound:

### Claim 4 (depends on 3)

A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the compound of claim 3.